Cervical cancer, the leading cause of mortality among women worldwide, is mainly caused by HPV infection. The oncogenic potential of the HR-HPV infection depends on the increased expressions of the E6 and E7 genes. The E6 and E7 proteins bind to the tumor suppressor proteins p53 and pRb respectively, and drive cervical cell proliferation and transformation.
However, HPV DNA testing confirms viral presence, it does not discern between latent and actively transcribing infections. In contrast, the detection of HPV E6/E7 mRNA transcripts serves as a more specific biomarker of active viral oncogene expression, and thus, is a more accurate predictor of underlying cervical intraepithelial neoplasia (CIN) or invasive carcinoma.
HPV E6/E7 mRNA testing offers significant advantages in cervical cancer prevention:
- Accurate Risk Assessment: Identifies active, high-risk HPV infections, providing a more precise risk assessment than HPV DNA testing.
- Effective Triage: Guides clinicians in identifying patients who need further investigation, reducing unnecessary procedures.
- Potential Screening Tool: May serve as a standalone screening tool in the future, especially for high-risk populations.
- 15 Types of High-risk Human Papillomavirus E6/E7 Gene mRNA Detection Kit (Fluorescence PCR) from #MMT, qualitatively detecting the marker for potentially progressive HR-HPV infections, is a useful tool for HPV screening and/or patient management.
Product features:
- Full coverage: 15 HR-HPV strains related with cervical cancer covered;
- Excellent sensitivity: 500 copies/mL;
- Superior specificity: No cross activity with cytomegalovirus, HSV II and human genomic DNA;
- Cost-effective: Testing targets more closely correlated with the possible disease, to minimize unnecessary examinations with extra costs;
- Excellent accuracy: IC for the whole process;
- Wide compatibility: With mainstream PCR systems;
Post time: Jul-25-2024